Epitranscriptome in Ischemic Cardiovascular Disease: Potential Target for Therapies

Area of Science:

• Molecular Biology
• Cardiovascular Research
• Epitranscriptomics

Background:

• Cardiovascular disease (CVD) remains a leading global cause of mortality, with atherosclerosis as a primary underlying pathology.
• The molecular mechanisms driving atherosclerosis are not fully elucidated, hindering effective early diagnosis and treatment.
• Epitranscriptomics, the study of RNA modifications, is rapidly advancing in other fields but remains underexplored in cardiovascular contexts.

Purpose of the Study:

• To review current research on epitranscriptomic modifications in cardiovascular disease.
• To highlight the roles of specific modifications like A-to-I editing and N6-methyladenosine (m6A) in atherogenesis.
• To explore the therapeutic potential of targeting epitranscriptomic mechanisms for cardiovascular conditions.

Main Methods:

• Literature review of recent studies on epitranscriptomics and cardiovascular disease.
• Focus on A-to-I RNA editing and N6-methyladenosine (m6A) modifications.
• Analysis of regulatory proteins involved in these epitranscriptomic processes.

Main Results:

• Epitranscriptomic modifications regulate RNA metabolism and cellular functions crucial for atherogenesis, such as cell proliferation.
• Specific epitranscriptomic mechanisms, including A-to-I editing and m6A, are implicated in cardiovascular disease development.
• These modifications offer potential novel checkpoints for gene expression regulation during disease progression.

Conclusions:

• Epitranscriptomic modifications represent a promising area for understanding and combating cardiovascular disease.
• Targeting RNA editing and methylation pathways could yield innovative therapeutic strategies for atherosclerosis and related conditions.
• Further research into epitranscriptomics is essential for advancing cardiovascular medicine.